Harbour BioMed and Lannacheng's Alliance Aiming for Radionuclide Drug Conjugate Innovations Harbour BioMed and Lannacheng join forces in a strategic partnership poised to innovate next-generation radionuclide drug conjugates for oncology treatments.

Harbour BioMed and Lannacheng's Alliance Aiming for Radionuclide Drug Conjugate Innovations #China #Shanghai #radiopharmaceuticals #Harbour_BioMed #Lannacheng